Karyopharm Therapeutics (KPTI) Change in Account Payables (2012 - 2025)

Karyopharm Therapeutics has reported Change in Account Payables for 14 years, with the latest figure at -$1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Account Payables fell 105.47% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2025 stood at -$1.1 million (down 155.65% YoY), and the FY2025 full-year result was -$1.1 million, down 155.65% from the prior year.
• Change in Account Payables for Q4 2025 stood at -$1.4 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $6.3 million in Q1 2023, with the low at -$6.8 million in Q2 2023.
• Historically, Change in Account Payables has averaged -$22350.0 across 5 years, with a median of -$703500.0 in 2021.
• Annual changes were most pronounced in 2021 — Change in Account Payables plunged 480.73% — and 2024, when it soared 322.17%.
• Karyopharm Therapeutics' Change in Account Payables stood at $722000.0 in 2021, then jumped by 171.47% to $2.0 million in 2022, then increased by 11.22% to $2.2 million in 2023, then sank by 131.01% to -$676000.0 in 2024, then tumbled by 105.47% to -$1.4 million in 2025.
• The last three Change in Account Payables figures came in at -$1.4 million (Q4 2025), $2.8 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.